Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempegaldesleukin + Nivolumab in Pediatric/Young Adult Malignancies
NCT04730349Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Cytokines & Interferons
- Countries
- 6
01
Overview
A Phase 2 trial of bempegaldesleukin in neuroblastoma, Ewing sarcoma, rhabdomyosarcoma (RMS), glioma, medulloblastoma, sponsored by Bristol Myers Squibb. Started Jun 2021; status: terminated.
02
Drugs
bempegaldesleukin
03
Conditions
neuroblastomaEwing sarcomarhabdomyosarcoma (RMS)gliomamedulloblastoma
Beyond the preview
Go deeper on NCT04730349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730349.